The scope of nanoparticle therapies for future metastatic melanoma treatment.
Norwich, United Kingdom. In Lancet Oncol, 31 Jan 2014
Some of the most promising therapies that have been developed include ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody that enhances T-cell activity in the tumour, and selective BRAF inhibitors, such as vemurafenib that blocks tumour cell proliferation in patients with activating BRAF mutations.
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Bonn, Germany. In Epilepsia, Dec 2013
The recent advent of new molecular markers, including genomic alterations leading to activation of the protooncogene BRAF and impaired function of isocitrate dehydrogenase (IDH1), provides excellent new tools in the differential diagnosis of low grade brain tumors, and provides intriguing implications to further develop the pathogenetic concepts of these neoplasms.